Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Genedrive secures US$1.4mln from US defence department for biohazard-detection device

Genedrive is further developing its handheld device to detect a broader range of biohazard targets
Genedrive
The device has had successful field trials

Genedrive PLC (LON:GDR) has secured a further US$1.4mln in funding from the US Department of Defence for its handheld biohazard-detection device programme.

The extra funding follows successful field trials on the portable device whereby officials assessed its potential to check for hazards such as biological warfare agents.

Genedrive will use the funds to further develop the device to detect a broader range of biohazard targets across multiple cartridges.

READ: Genedrive making “good progress” as revenues rise across board, Hep-C assay nears EU approval

The company said the aim of the programme is to develop a “cost-effective system that would allow multiple units and tests to be deployed for field use”.

The latest funding brings the total it has received from the Department of Defence to US$6.5mln.

The next stage of the programme is expected to generate about US$1.4mln in development income for the year to 30 June 2018.

"This next phase of field testing will help to further validate and confirm the characteristics of the Genedrive system: portability, flexibility and accuracy,” said Genedrive’s chief executive, David Budd.

 “The evaluation will be far reaching, rigorous and, if successful, it will be a clear validation of the Genedrive unit as a robust and easily deployable hand held device for pathogen and disease detection."

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

generic pill and bottle shot to denote Alliance's products
August 14 2017
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?
newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
biotech2.jpg
August 18 2017
The company operates a hybrid model, which means its revenues come from providing antibody research and engineering services and creating drug conjugates (targeted treatments for diseases such as cancer). It also manufactures antibodies and proteins for clinical studies

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use